null - Allergan Breast Implant Lawsuit

People's Justice Research TeamUpdated February 21, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

How BIA-ALCL Is Staged — The MD Anderson System

BIA-ALCL is staged using the MD Anderson Cancer Center Solid Tumor Staging System for BIA-ALCL — not the traditional Ann Arbor system used for most lymphomas — because BIA-ALCL behaves differently from other lymphomas in its initial localized presentation. The MD Anderson system classifies BIA-ALCL based on how far the disease has spread from its origin in the peri-implant fluid or capsule. Diagnosis is made by ultrasound-guided aspiration of seroma fluid and cytological analysis (finding atypical large lymphoma cells expressing CD30, a cell-surface marker), or by capsule biopsy. The stage at diagnosis drives both treatment decisions and legal compensation value.

Stage IA — Seroma-Confined Disease

Stage IA is the earliest and most favorable stage. Lymphoma cells are found only in the seroma fluid or on the inner surface of the fibrous capsule — they have not penetrated the capsule wall. Treatment: complete en bloc capsulectomy (surgical removal of the implant together with the entire surrounding capsule as one intact specimen). When performed with clean margins (no residual disease), Stage IA is typically curable without chemotherapy. Estimated legal compensation range: $50,000 to $300,000. Despite favorable prognosis, Stage IA patients experienced a cancer diagnosis, underwent major surgery, face ongoing surveillance, and lived with the psychological burden of cancer from an elective or reconstructive device — all of which constitute compensable damages.

Stage IB and Stage II — Capsule and Lymph Node Involvement

Stage IB: lymphoma cells have penetrated through to the outer surface of the fibrous capsule. Treatment continues to center on surgery but with closer margins monitoring and more likely adjuvant chemotherapy. Stage IIA: a single regional lymph node (typically axillary — armpit — lymph node) is involved. Stage IIB: multiple lymph nodes in one region are involved. Stage II treatment: surgery followed by CHOP-based chemotherapy (typically 6 cycles), which substantially increases treatment burden, side effects (nausea, hair loss, fatigue, peripheral neuropathy, increased infection risk), and recovery time. Estimated legal compensation range for Stage IB–IIA: $300,000 to $900,000. Stage IIB: $500,000 to $1,200,000.

Stage III and Stage IV — Advanced and Metastatic Disease

Stage III: disease has invaded adjacent structures — the chest wall, skin, or breast tissue. Treatment requires aggressive multimodal therapy. Stage IV: distant metastases to organs such as the liver, lungs, bone, or central nervous system — the most serious BIA-ALCL stage with the worst prognosis. Stage IV treatment includes intensive chemotherapy, potentially including brentuximab vedotin (anti-CD30 targeted therapy) and autologous stem cell transplant for eligible patients. Prognosis for Stage IV BIA-ALCL is significantly worse than early-stage disease, with 5-year survival rates substantially reduced. Estimated legal compensation range: Stage III — $700,000 to $1,500,000. Stage IV — $1,000,000 to $3,000,000 or more. Wrongful death cases from BIA-ALCL have commanded the highest valuations in comparable medical device MDLs. Stage at diagnosis is documented in pathology reports; an attorney will obtain all relevant records during case evaluation.

FAQ

Frequently Asked Questions

12 QUESTIONS

BIA-ALCL stands for breast implant-associated anaplastic large cell lymphoma. It is a rare cancer of the immune system — specifically a T-cell lymphoma — that develops in the fluid or scar tissue capsule surrounding a breast implant, not in the breast tissue itself. The FDA has definitively established that BIA-ALCL is associated with textured breast implant surfaces, and Allergan's BIOCELL macro-textured surface in particular. As of June 2023, 1,079 of 1,264 globally reported BIA-ALCL cases (85%) involved Allergan BIOCELL implants. The FDA determined that women with Allergan BIOCELL implants face approximately a 6x higher risk of developing BIA-ALCL compared to women with implants from other manufacturers. The working hypothesis is that the BIOCELL surface's macro-texture creates a chronic inflammatory micro-environment that, over years, can trigger malignant T-cell transformation. This is why the recall targeted Allergan's BIOCELL surface specifically, not breast implants generally.

All BIOCELL textured breast implants and tissue expanders were recalled on July 24, 2019. The major recalled products include: Natrelle 410 Highly Cohesive Anatomically Shaped implants (all styles: FM, FF, MM, MF, ML, LL, LM, LF, FX, MX, LX — the most widely implanted recalled model); Natrelle Silicone-Filled Textured implants (styles TRL, TRM, TRF, TRX, TSL, TSM, TSF, TSX); Natrelle Saline-Filled Textured implants (styles 163, 168, 363, 468); Natrelle Inspira Textured implants; McGhan Textured Breast Implants (predecessor brand under same recall); and BIOCELL Tissue Expanders (Natrelle 133 series). Smooth-surface Allergan implants — including smooth Natrelle Inspira and Microcell lines — were NOT recalled. If you are unsure whether your implants are BIOCELL, request your implant identification card from your surgeon or review your operative report for the style number.

No. BIA-ALCL is the primary claim in MDL 2921, but it is not the only basis for filing. Women who underwent explant surgery to remove recalled Allergan BIOCELL implants — even without a BIA-ALCL diagnosis — may have claims for surgery costs, lost wages, pain and suffering, and the distress of undergoing an unplanned surgical procedure. Women experiencing breast implant illness (BII) symptoms attributed to their BIOCELL implants are also included in MDL 2921, though BII claims face greater legal challenges than BIA-ALCL claims. If you have BIOCELL implants and are monitoring without removal, and you later develop BIA-ALCL, your statute of limitations typically begins at diagnosis. Consult an attorney to understand your current options based on your specific situation.

The most common first symptom of BIA-ALCL is late-onset seroma — a sudden, persistent accumulation of fluid around the implant that appears an average of 8 to 10 years after implant placement. Unlike normal post-surgical seroma that resolves within months of the original implant surgery, BIA-ALCL-related seroma appears late and does not resolve on its own. Other symptoms include: breast swelling, asymmetry, or a noticeable change in implant shape; a palpable lump in the breast or armpit; breast pain or tenderness; skin rash or redness over the implant area; and swollen lymph nodes in the armpit. If you have Allergan BIOCELL implants and experience any of these symptoms — especially late-onset fluid accumulation — contact your plastic surgeon immediately and request an ultrasound-guided aspiration to test the fluid for lymphoma cells. Early detection dramatically improves outcomes.

No global Allergan settlement has been announced as of February 2026. The first bellwether trial in MDL 2921 is scheduled for October 2026 and will be the primary driver of settlement negotiations. Based on comparable medical device mass tort MDLs — including metal-on-metal hip implant cases and hernia mesh litigation — individual claim values depend heavily on the severity of injury. BIA-ALCL Stage IA cases treated with surgical excision only are estimated in the $50,000 to $300,000 range. Stage II–III cases requiring chemotherapy are estimated at $300,000 to $1,500,000. Stage IV metastatic BIA-ALCL cases may command $1,000,000 to $3,000,000 or more. Wrongful death claims from BIA-ALCL carry the highest values. Women who underwent explant surgery without a cancer diagnosis have lower valuations, primarily covering surgery costs, lost wages, and distress. Women who received implants for post-mastectomy reconstruction following breast cancer may present particularly compelling damages narratives.

Yes. Having your BIOCELL implants removed does not bar you from filing a claim. In fact, many claimants in MDL 2921 had their implants removed before or after the 2019 recall and are seeking compensation for the surgery costs, emotional distress, and disruption to their lives caused by having to undergo an unplanned explantation. If you were diagnosed with BIA-ALCL before your implants were removed, your cancer claim proceeds regardless of implant status. The key question is whether your claim is within the applicable statute of limitations, which depends on your state and the date you knew or should have known of the BIOCELL connection to your injury. An attorney can evaluate your specific situation, including whether MDL tolling agreements protect your claim if you previously enrolled.

MDL 2921 — In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation — is a federal multidistrict litigation consolidating Allergan breast implant cases from across the United States in the U.S. District Court for the District of New Jersey. It was created by the Judicial Panel on Multidistrict Litigation in December 2019 and is presided over by Judge Brian R. Martinotti. An MDL is not a class action — each plaintiff retains an individual claim and individual damages. The MDL consolidates pretrial proceedings (discovery, expert testimony, motions) to avoid duplicative proceedings across hundreds of individual cases. Bellwether trials — individual cases tried to provide settlement data — are the next major milestone, with the first trial scheduled for October 2026. If Allergan and plaintiffs' leadership reach a global settlement, each enrolled plaintiff will be evaluated for compensation based on their specific diagnosis and damages under a settlement grid negotiated between the parties.

BIA-ALCL is not breast cancer. This distinction matters legally and medically. Breast cancer originates in the breast tissue — in the ductal or lobular cells of the mammary gland. BIA-ALCL originates in the immune system — specifically in T-lymphocytes that accumulate in the fluid or scar tissue capsule surrounding the implant. BIA-ALCL is a lymphoma, classified under non-Hodgkin lymphomas, not under breast cancer. This means it is treated by oncologists specializing in lymphoma, not breast cancer oncologists, and it responds to lymphoma-specific treatments (CHOP chemotherapy, brentuximab vedotin) rather than breast cancer treatments (tamoxifen, HER2-targeted therapy). Legally, this distinction reinforces the directness of the causal link to Allergan's product — BIA-ALCL does not arise from breast tissue genetics or family history; it arises from the implant's interaction with the immune system.

The statute of limitations varies by state but is typically 2 to 3 years from the date you knew or should have known that your Allergan BIOCELL implants caused your injury — the discovery rule. For BIA-ALCL, this typically means from the date of diagnosis. For explant costs, it may mean from the date of surgery or from the July 2019 recall (whichever is later under your state's discovery rule). Key deadlines: California — 2 years from discovery (CCP § 335.1); Texas — 2 years from discovery (Tex. Civ. Prac. § 16.003); Florida — 2 years from discovery (§ 95.11(3)(a)); New York — 3 years from discovery for personal injury. The District of New Jersey (where MDL 2921 is pending) applies the law of the state where the implant was placed. MDL 2921 tolling agreements have preserved many claims, but these do not automatically apply to new claimants. Consult an attorney immediately — do not attempt to self-evaluate complex tolling questions.

Yes — this is a central allegation in MDL 2921. The FDA first publicly communicated a possible link between breast implants and BIA-ALCL in January 2011. French regulators identified a disproportionate risk specifically from Allergan's BIOCELL implants and recalled them in December 2018 — a full year before the U.S. recall. Despite accumulating case reports in the FDA's MAUDE database showing a marked overrepresentation of Allergan BIOCELL implants in BIA-ALCL cases throughout the early 2010s, Allergan did not strengthen its BIA-ALCL warning language in a way plaintiffs' attorneys argue was adequate, and did not initiate a U.S. recall until July 2019. The 8-year gap between FDA's first warning (2011) and Allergan's recall (2019) is the core of failure-to-warn claims in MDL 2921. Plaintiffs allege Allergan prioritized BIOCELL sales over patient safety during this period.

Key evidence for an Allergan claim includes: (1) Implant identification — your implant card (given at time of surgery), operative report, or surgeon records confirming Allergan BIOCELL product name and style number; (2) Medical records — pathology report confirming BIA-ALCL diagnosis with staging, or surgical records for explant procedure; (3) Treatment records — oncology records, chemotherapy administration records, imaging studies (ultrasound, PET-CT), and surgical reports; (4) Economic damages documentation — medical bills, insurance explanation of benefits, pay stubs and records of missed work, out-of-pocket expenses. You do not need the implants themselves (which will have been removed and likely sent to pathology). Your attorney can obtain medical records, operative reports, and implant identification information with your authorization. Women who had implants placed at multiple facilities or by multiple surgeons should gather records from all treating providers.

Treatment for BIA-ALCL depends on disease stage at diagnosis. For Stage IA (disease confined to seroma fluid or inner capsule), the recommended treatment is complete en bloc capsulectomy — surgical removal of the implant together with the entire surrounding fibrous capsule in one intact specimen. This approach is curative in the majority of Stage IA cases, with high rates of complete remission without chemotherapy. For Stage IB–III disease (capsule involvement, lymph node spread), surgery is followed by systemic chemotherapy, typically CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Brentuximab vedotin — a CD30-targeted antibody-drug conjugate — has shown strong efficacy in BIA-ALCL and is used in some regimens. Stage IV disease may require autologous stem cell transplant in eligible patients. The NCCN (National Comprehensive Cancer Network) guidelines recommend referral to a lymphoma specialist with BIA-ALCL experience. After treatment, regular PET-CT surveillance is recommended to monitor for recurrence.

The full investigation

Part of the Allergan Breast Implant Investigation

Allergan Breast Implant LawsuitAllergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.CASE OVERVIEW

Quick Eligibility Review

Check your eligibility — free

How BIA-ALCL Is Staged — The MD Anderson System

Stage IA — Seroma-Confined Disease

Stage IB and Stage II — Capsule and Lymph Node Involvement

Stage III and Stage IV — Advanced and Metastatic Disease

Frequently Asked Questions

What is BIA-ALCL and why is it linked to Allergan implants?

Which Allergan implants were recalled?

Do I need a BIA-ALCL diagnosis to file an Allergan lawsuit?

What are the symptoms of BIA-ALCL?

How much is the Allergan breast implant settlement worth?

Can I still sue if my Allergan implants were already removed?

What is MDL 2921 and how does it work?

What is the difference between BIA-ALCL and breast cancer?

What is the statute of limitations for the Allergan breast implant lawsuit?

Did Allergan know about the BIA-ALCL risk before the 2019 recall?

What evidence do I need for an Allergan breast implant lawsuit?

What is the recommended treatment for BIA-ALCL?

Part of the Allergan Breast Implant Investigation